Hydrochloride, Mianserin,
Lerivon,
Mianserin,
Mianserin Hydrochloride,
Mianserin Monohydrochloride,
Monohydrochloride, Mianserin,
Org GB 94,
Tolvon,
Mianserin hydrochloride,
21535-47-7,
Mianserin HCl,
Mianserine hydrochloride,
Tolvon,
Bolvidon,
Athymil,
Norval,
Tolvin,
Mianserin (hydrochloride),
ORG GB 94,
Lerivon,
MLS000069681,
ORG GB-94 HCl,
SMR000058472,
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride,
GB 94,
EINECS 244-426-7,
Mianserin hydrochloride [USAN:JAN],
MFCD00055072,
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine monohydrochloride,
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine hydrochloride,
1,2,3,4,10,14beta-Hexahydro-2-methyldibenzo[c,f]pyryzino[1,2-a]azepine hydrochloride,
2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride,
Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, monohydrochloride,
CHEBI:31843,
SR-01000000185,
mianserine HCl,
Tetramide (TN),
Prestwick_514,
Mianserin Hydrocloride,
mianserin-hydrochloride,
Bolvidon;Norval;Tolvon,
(.+-.)-Athymil,
Opera_ID_1505,
(.+-.)-Norval,
AC1L29ZA,
AC1Q38XJ,
C18H20N2.HCl,
cid_68551,
MLS001148213,
MLS002222220,
SCHEMBL340474,
SPECTRUM2300292,
CHEMBL544428,
BDBM31005,
CTK4F3129,
HY-B0188A,
KS-00000ZQX,
HMS1568C20,
Pharmakon1600-02300292,
BCP09259,
EBD23593,
Mianserin hydrochloride (JAN/USAN),
Tox21_500744,
AN-730,
CCG-39108,
NSC292267,
NSC759590,
s1382,
AKOS015902308,
API0005729,
CS-2079,
KS-5096,
LP00744,
NSC-292267,
NSC-759590,
VA11292,
2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride(1:1),
NCGC00094086-01,
NCGC00094086-02,
NCGC00094086-03,
NCGC00094086-04,
NCGC00261429-01,
AC-25005,
BC683953,
LS-61198,
SC-14149,
AB0008516,
AB2000076,
TX-017754,
AK00565511,
EU-0100744,
FT-0628940,
M2623,
SW196707-3,
D01358,
M 2525,
535M477,
SR-01000000185-2,
SR-01000000185-4,
SR-01000000185-8,
W-111733,
I14-13356,
Mianserin Hydrochloride 1.0 mg/ml in Methanol (as free base),
Mianserin hydrochloride, analytical standard, for drug analysis,
Dibenzo[c,f]pyrazino[1,2-a]azepine,1,2,3,4,10,14b-hexahydro-2-methyl-,
Mianserin hydrochloride, European Pharmacopoeia (EP) Reference Standard,
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyryzino[1,2-a]azepine hydrochloride,
Mianserin for system suitability, European Pharmacopoeia (EP) Reference Standard,
5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7.0^{8,13]nonadeca-1(19),8,10,12,15,17-hexaene;hydrochloride,
5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene hydrochloride,
78644-54-9,
Bolvidon; 1,2,3,4,10,14b-Hexahydro-2-methyl-dibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride,
Mianserin hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material,
mianserin,
Prazosin hydrochloride,
C18H21ClN2,
UNII-2X03TN217S,
2X03TN217S,
CID68551,
AR-1E3312,
1701B,
2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine,
24219-97-4,
1,2,3,4,10,14b-Hexahydro-2-methyl-dibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride,
19237-84-4,
24813-03-4,